Achieve Life Sciences Inc (ACHV): Next-Year EPS Estimate 54.51%
As of 2026-08-26, Achieve Life Sciences Inc (ACHV) has a next-year EPS growth estimate of 54.51%. Featured in our EPS revision report on 2026-08-19.
On 2026-08-20, analyst consensus for ACHV's next-year EPS growth shifted from 54.98% to 54.51% — a negative change of 0.47 percentage points. The revised estimate has been sustained across 6 subsequent trading sessions. Current-year growth is projected at -16.72%.
What's Driving This
The primary driver of ACHV's rise is the upward revision to next-year EPS growth estimates, which were boosted from 43.50% to 49.79% on 2026-08-13 and now stand at 54.51%. Headlines cite quarterly financial results and business updates, but no explicit earnings beat, contract win, or guidance raise is identified as the specific catalyst. Momentum has continued beyond the initial revision, with a net +23.86 percentage-point gain across six upward moves and one downward move since detection.
Generated 2026-08-26 from news as of 2026-08-26
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 54.51%
- EPS growth this year
- -16.72%
- EPS next quarter (est)
- -$0.20
- Last price
- $8.18
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-26 | 54.51% | -16.72% | -$0.20 | $8.18 |
| 2026-08-25 | 54.51% | -16.72% | -$0.20 | $8.17 |
| 2026-08-24 | 54.51% | -16.72% | -$0.20 | $7.94 |
| 2026-08-23 | 54.51% | -16.72% | -$0.20 | $7.99 |
| 2026-08-21 | 54.51% | -16.72% | -$0.20 | $7.99 |
| 2026-08-20 | 54.51% | -16.72% | -$0.20 | $8.02 |
| 2026-08-19 | 54.98% | -10.18% | -$0.19 | $8.53 |
| 2026-08-18 | 54.98% | -10.18% | -$0.19 | $7.52 |
| 2026-08-17 | 53.06% | -5.67% | -$0.19 | $7.50 |
| 2026-08-16 | 53.06% | -5.67% | -$0.19 | $7.59 |
| 2026-08-14 | 50.91% | -0.36% | -$0.19 | $7.59 |
| 2026-08-13 | 49.79% | 6.25% | -$0.18 | $7.25 |
| 2026-08-12 | 43.50% | 15.04% | -$0.18 | $6.69 |
| 2026-08-11 | 31.19% | 31.80% | -$0.18 | $6.77 |
| 2026-08-03 | 30.65% | 43.59% | -$0.16 | $6.32 |
| 2026-08-02 | 30.65% | 43.59% | -$0.16 | $6.42 |
| 2026-07-31 | 30.65% | 43.59% | -$0.16 | $6.42 |
| 2026-07-30 | 30.65% | 43.59% | -$0.16 | $6.30 |
| 2026-07-29 | 30.65% | 43.59% | -$0.16 | $6.18 |
| 2026-07-28 | 30.65% | 43.59% | -$0.16 | $6.18 |
| 2026-07-27 | 30.65% | 43.59% | -$0.16 | $6.18 |
| 2026-07-26 | 30.65% | 43.59% | -$0.16 | $6.10 |
| 2026-07-24 | 30.65% | 43.59% | -$0.16 | $6.10 |
| 2026-07-23 | 30.65% | 43.59% | -$0.16 | $6.17 |
| 2026-07-22 | 30.65% | 43.59% | -$0.16 | $6.31 |
| 2026-07-21 | 30.65% | 43.59% | -$0.16 | $6.50 |
| 2026-07-20 | 30.65% | 43.59% | -$0.16 | $6.24 |
| 2026-07-19 | 30.65% | 43.59% | -$0.16 | $6.27 |
| 2026-07-17 | 30.65% | 43.59% | -$0.16 | $6.27 |
| 2026-07-16 | 30.65% | 43.59% | -$0.16 | $5.96 |
Reports Featuring ACHV
Recent News
- Achieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire
- Achieve Life Sciences Inc (ACHV) Q1 2026 Earnings Call Highlights: Strategic Financing and ...GuruFocus.com
- Achieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona PharmaGlobeNewswire
- Achieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire
- Achieve Life Sciences Inc (ACHV) Q4 2025 Earnings Call Highlights: Strategic Advances and ...GuruFocus.com
- Achieve Life Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesNewsfile
- Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewswire
Screen Performance
Aggregate stats across all 2015 tickers our top-EPS-revision screen has flagged over the past 147 days.
- Median return since detection
- +3.0%
- % of tickers in the green
- 56%
- Median return on winners
- +20.0%
- Large revisions captured
- 1609
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Achieve Life Sciences Inc's next-year EPS growth estimate?▾
As of 2026-08-26, Achieve Life Sciences Inc (ACHV) has a next-year EPS growth estimate of 54.51%, based on analyst consensus.
When was the latest EPS estimate revision for ACHV?▾
The most recent revision occurred on 2026-08-20, when analysts adjusted the next-year EPS growth estimate from 54.98% to 54.51%.
What sector and industry does Achieve Life Sciences Inc belong to?▾
Achieve Life Sciences Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. ACHV appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Achieve Life Sciences Inc (ACHV) appears here because it was detected by our daily top-EPS-revision-performer screen.